Bliss GVS Pharma Files Certificate Under SEBI Depositories Regulations for Q4 FY26
Bliss GVS Pharma Limited has filed a certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. The certificate was provided by the Registrar and Share Transfer Agent, MUFG Intime India Private Limited.
This is a standard compliance filing related to share dematerialisation and does not involve any significant corporate actions or financial performance indicators.
The announcement is a routine regulatory filing and does not contain any information that would positively or negatively impact the company's stock.
Bliss GVS Pharma Limited has submitted a certificate received from MUFG Intime India Private Limited, the company's Registrar and Share Transfer Agent. This certificate is in compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.
The certificate pertains to the quarter ended March 31, 2026. MUFG Intime India Private Limited confirmed that securities received from depository participants for dematerialisation during the said quarter were processed and confirmed with the depositories. They also confirmed that the security certificates received were mutilated and cancelled after verification, and the depositories' names were substituted in the register of members within the prescribed timelines.
The company has requested that this information be taken on record.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.